P489: PROGNOSTIC IMPACT OF “MULTI-HIT” VERSUS “SINGLE-HIT” TP53 MUTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS FROM THE CONSORTIUM ON MYELOID MALIGNANCIES AND NEOPLASTIC DISEASES (COMMAND)

• Talha Badar,
• Ehab Atallah,
• Rory M. Shallis,
• Aaron D Goldberg,
• Ahmad Nanaa,
• Antoine Saliba,
• Anand Patel,
• Jan Bewersdorf,
• Adam Duvall,
• Madelyn Burkart,
• Danielle Bradshaw,
• Yasmin Abaza,
• Maximillian Stahl,
• Neil Palmisiano,
• Guru Subramanian Guru Murthy,
• Vamsi Kota,
• Amer M. Zeidan,
• Mark Litzow

Affiliations

Talha Badar

1 Mayo Clinic, Jacksonville, United States

Ehab Atallah

2 Medical College of Wisconsin, Milwaukee, United States

Rory M. Shallis

3 Yale University, New Haven, United States

Aaron D Goldberg

4 Memorial Sloan Kettering Cancer Center New York, New York, United States

Ahmad Nanaa

5 Mayo Clinic, Rochester, United States

Antoine Saliba

5 Mayo Clinic, Rochester, United States

Anand Patel

6 The University of Chicago, Chicago, United States

Jan Bewersdorf

3 Yale University, New Haven, United States

Adam Duvall

6 The University of Chicago, Chicago, United States

Madelyn Burkart

7 Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, United States

Danielle Bradshaw

8 Augusta, Augusta, United States

Yasmin Abaza

7 Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, United States

Maximillian Stahl

9 Dana-Farber Cancer Institute, Boston, United States

Neil Palmisiano

10 Sidney Kimmel Cancer Center – Jefferson Health, Philadelphia, United States

Guru Subramanian Guru Murthy

2 Medical College of Wisconsin, Milwaukee, United States

Vamsi Kota

11 Georgia Cancer Center Outpatient Sevices, Augusta, United States

Amer M. Zeidan

3 Yale University, New Haven, United States

Mark Litzow

5 Mayo Clinic, Rochester, United States